EyeCon chair Kelly K. Nichols, OD, PhD, MPH, FAAO shares some of her favorite moments throughout her career and what inspires her to continue pushing the industry forward.

The SCANLY Home OCT device allows physicians to monitor patients’ wet age-related macular degeneration in between visits through a health cloud portal.

Michael Chaglasian, OD, details results from a study that assessed the new Monaco OCT's efficacy in glaucoma detection alongside ultra wideview imaging.

The microemulsion drug ocular penetration system platform technology was found to effectively formulate and deliver lipophilic molecules via topical eye drops.

The Early Detection of Vision Impairment in Children (EDVI) Act was recently introduced in the US House of Representatives with the goal of improving access, diagnosis, and treatment for children ages 2 to 17, according to Prevent Blindness.

Considering recovery time, potential adverse effects, and future eye care needs can increase patient satisfaction.

Emily Chew, MD, who won this year's Proctor Award, outlines her presentation on preparing for estimated doubling of age-related macular degeneration cases in the next 25 years at ARVO 2024.

Noel Brennan, MScOptom, PhD, overviews his ARVO 2024 presentation on reimagining the prediction of longer term efficacy numbers in data from pediatric trials evaluating myopia.

Preventive options should be as important as treating symptoms

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

Honest discussions about treatments for dry eye disease can enhance compliance and simplify care.

Ricardo Pintor, OD, FIACLE, gives an overview of the World Council of Optometry’s first Latin America–based virtual event and what challenges Latin America faces in terms of myopia.

Catch up on what happened in optometry during the week of May 6-May 10.

The clinical-stage biopharmaceutical company has enrolled 15 participants in its study to assess the safety and tolerability of ACT107 in 3 dose strengths.

Deborah Ferrington, chief scientific officer at Doheny Eye Institute, details a session she gave on May 9 regarding mitochondria and how they change with health and in the diseased retina.